Cytosorbents (CTSO) Net Cash Flow Growth (3y) (2013 - 2026)
Cytosorbents (CTSO) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 269.22% |
| 10 | Cytosorbents | 21.98 Mn | 17.56 Mn | 7.05 Mn | 53.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.85% |
| Mar 31, 2026 | 27.01% |
| Dec 31, 2025 | -69.01% |
| Sep 30, 2025 | 30.31% |
| Jun 30, 2025 | 49.48% |
| Mar 31, 2025 | 33.30% |
| Dec 31, 2024 | 31.80% |
| Sep 30, 2024 | 14.40% |
| Jun 30, 2024 | 54.70% |
| Mar 31, 2024 | -24.37% |
| Dec 31, 2023 | 32.84% |
| Sep 30, 2023 | -27.88% |
| Jun 30, 2023 | -38.83% |
| Mar 31, 2023 | -30.44% |
| Dec 31, 2022 | 47.40% |
| Sep 30, 2022 | -190.68% |
| Jun 30, 2022 | -56.25% |
| Mar 31, 2022 | -49.29% |
| Dec 31, 2021 | -41.54% |
| Sep 30, 2021 | -136.73% |